secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001104659-24-022648
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx receives $5M advance milestone from Alvogen/Lotus, issues 4.2M warrants at $0.40
--------------------------------------------------------------------------------

- $5M received immediately; funds NRX-101 development through Phase 2 FDA meeting.
- Alvogen receives 4,195,978 warrants at $0.40 strike, 3-year term.
- Second $4M milestone due within 60 days of positive end-of-Phase 2 FDA meeting.
- NRx eligible for up to $320M in future milestones and tiered double-digit royalties.
- Alvogen/Lotus to cover future NRX-101 development and commercialization costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/0001104659-24-022648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/tm246184d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-022648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer